Cytokinetics, Incorporated
CYTK
Κατάταξη σε μετοχές
#2263
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Τιμή μετοχής
$62.83
Τελευταίος συγχρονισμός: 2026-10-21
Κεφαλαιοποίηση
$8.73B
Αλλαγή (1 ημέρα)
-1.75%
Αλλαγή (1 έτος)
14.73%
Χώρα
US
Εμπόριο Cytokinetics, Incorporated (CYTK)
Κατηγορία
Healthcare
Ιστορικό τιμής μετοχής για την Cytokinetics, Incorporated (CYTK)
Υψηλότερη τιμή κλεισίματος: $62.96 στις 2026-10-01
Χαμηλότερη τιμή κλεισίματος: $97.08 στις 2004-04-01
Χαμηλότερη τιμή κλεισίματος: $97.08 στις 2004-04-01
Ιστορικό τιμής μετοχής της Cytokinetics, Incorporated από 2004 έως 2026
Ετήσια απόδοση τιμής μετοχής
| Έτος | Απόδοση |
|---|---|
| 2026 (TTM) | 8.70% |
| 2025 | 28.55% |
| 2024 | 11.95% |
| 2023 | 4.76% |
| 2022 | 4.97% |
| 2021 | 101.81% |
| 2020 | 97.15% |
| 2019 | 42.08% |
| 2018 | -14.22% |
| 2017 | -29.65% |
| 2016 | 4.66% |
| 2015 | 114.65% |
| 2014 | -19.66% |
| 2013 | 59.81% |
| 2012 | -32.39% |
| 2011 | -55.97% |
| 2010 | -23.56% |
| 2009 | 26.62% |
| 2008 | -55.25% |
| 2007 | -26.58% |
| 2006 | -3.72% |
| 2005 | -20.38% |
| 2004 | 0.00% |
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Τιμή μετοχής | Μεταβολή 1Έτ% | Χώρα |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.24 | 7.63% |
CH
|
